Cook Reconsiders Logic Of Drug-Eluting Stents As Guidant Deal Unravels
This article was originally published in The Gray Sheet
Executive Summary
Cook Group is considering re-starting the 1,200-patient, six-center PATENCY pivotal trial of its Logic PTX paclitaxel-eluting coronary stent
You may also be interested in...
Guidant’s last stand on paclitaxel
Company's paclitaxel-eluting stent program achieves closure with federal appeals court affirmation of lower court ruling that Cook's deal with Guidant violated a co-exclusive license agreement among Boston Scientific, Cook and Angiotech. The program already had been terminated due to poor DELIVER study results; in January, Guidant scuttled a proposed merger with Cook. Guidant is exploring an everolimus-eluting stent (1"The Gray Sheet" Jan 6, 2003, p. 4). Boston Scientific submits the fifth and final PMA module for its Taxus paclitaxel-eluting stent...
Guidant’s last stand on paclitaxel
Company's paclitaxel-eluting stent program achieves closure with federal appeals court affirmation of lower court ruling that Cook's deal with Guidant violated a co-exclusive license agreement among Boston Scientific, Cook and Angiotech. The program already had been terminated due to poor DELIVER study results; in January, Guidant scuttled a proposed merger with Cook. Guidant is exploring an everolimus-eluting stent (1"The Gray Sheet" Jan 6, 2003, p. 4). Boston Scientific submits the fifth and final PMA module for its Taxus paclitaxel-eluting stent...
Guidant Shuffles Capek, Boosts Delivery Options With X-Technologies Buy
Guidant is turning to a polished communications, organizational and policy executive to oversee its vascular intervention business with the elevation of company veteran Dana Mead